Evidence map›Paper›PMID 27694900›Full record

ArticleOncogene2017

Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.

S Ramadoss, S Sen, I Ramachandran, S Roy, G Chaudhuri, R Farias-Eisner

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 73 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Epigenetic regulation of cancer stemness.Signal transduction and targeted therapy · 2025
    Review
  7. Lysine and arginine methylation of transcription factors.Cellular and molecular life sciences : CMLS · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Targeting epigenetic regulators to overcome drug resistance in cancers.Signal transduction and targeted therapy · 2023
    Review
  14. Article
  15. Review
  16. microRNA-155-3p attenuates intervertebral disc degeneration via inhibition of KDM3A and HIF1α.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

S RamadossDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
S SenDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
I RamachandranDepartment of Endocrinology, Dr ALM PG Institute of Basic Medical Sciences, University of Madras, Taramani Campus, Chennai 600 113, Tamil Nadu, India.
S RoyDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
G ChaudhuriDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
R Farias-EisnerDepartment of Obstetrics and Gynecology, David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
University of California, Los Angeles · USUniversity of Madras · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer is the leading cause of death among all gynecological malignancies due to the development of acquired chemoresistance and disease relapse. Although the role of cancer stem cells (CSCs), a subset of tumor cells with the self-renewal and differentiation capabilities, in therapeutic resistance is beginning to be better understood, the significance of epigenetic regulatory mechanisms responsible for integrating the stemness with drug resistance remain poorly understood. Here we identified that lysine demethylase KDM3A as a critical regulator of ovarian cancer stemness and cisplatin resistance by inducing the expressions of pluripotent molecules Sox2 and Nanog and anti-apoptotic B-cell lymphoma 2 (Bcl-2), respectively. In addition, KDM3A induces ovarian cancer growth while antagonizing cellular senescence by repressing the expression of cyclin-dependent kinase inhibitor, p21

Indexed as

AnimalsAntineoplastic AgentsApoptosisCell CycleCell Line, TumorCellular SenescenceCisplatinCyclin-Dependent Kinase Inhibitor p21Disease Models, AnimalDrug Resistance, NeoplasmEpigenesis, GeneticFemaleGene ExpressionGene Knockdown TechniquesHeterograftsHumansAntineoplastic AgentsCisplatinCyclin-Dependent Kinase Inhibitor p21Jumonji Domain-Containing Histone DemethylasesKDM3A protein, humanLysineProto-Oncogene Proteins c-bcl-2SOXB1 Transcription FactorsTumor Suppressor Protein p53

Identifiers

PMID27694900
PMCPMC5357761
OpenAlexW2529083907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.